ACRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Aclaris Therapeutics's Net Income for the three months ended in Sep. 2024 was $-7.59 Mil. Aclaris Therapeutics's Revenue for the three months ended in Sep. 2024 was $4.35 Mil. Therefore, Aclaris Therapeutics's net margin for the quarter that ended in Sep. 2024 was -174.55%.
The historical rank and industry rank for Aclaris Therapeutics's Net Margin % or its related term are showing as below:
The historical data trend for Aclaris Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Margin % | Get a 7-Day Free Trial | -3,817.22 | -787.03 | -1,343.96 | -292.11 | -283.15 |
Aclaris Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Net Margin % | Get a 7-Day Free Trial | -315.24 | -8.49 | -706.46 | -397.18 | -174.55 |
For the Diagnostics & Research subindustry, Aclaris Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Aclaris Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
Net Margin | = | Net Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -88.481 | / | 31.249 | |
= | -283.15 % |
Aclaris Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as
Net Margin | = | Net Income (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | -7.586 | / | 4.346 | |
= | -174.55 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics (NAS:ACRS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Aclaris Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Anand Mehra | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Joseph Monahan | officer: Chief Scientific Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Kevin Balthaser | officer: Chief Financial Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
James Loerop | officer: Chief Business Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Douglas J. Manion | officer: Pres and COO | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Neal Walker | director, officer: President and CEO | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Andrew N Schiff | director | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Gail Cawkwell | officer: Chief Medical Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Frank Ruffo | officer: Chief Financial Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
David N. Gordon | officer: Chief Medical Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Kamil Ali-jackson | officer: Chief Legal Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
James B. Tananbaum | 10 percent owner | 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115 |
Foresite Capital Management Iii, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Foresite Capital Fund Iii, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Fund Iv, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
From GuruFocus
By Marketwired • 09-17-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 05-07-2024
By Marketwired • 04-30-2024
By GuruFocus Research • 02-06-2024
By GuruFocus News • 11-15-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 06-06-2024
By GuruFocus News • 11-21-2024
By Marketwired • 12-03-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.